Meridian Clinical Research - Family Practice
Welcome,         Profile    Billing    Logout  
 0 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Myneni, Banu
NCT06229145: A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

Recruiting
4
240
US
Pegloticase, Methotrexate
Amgen
Gout
09/25
05/26
NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Recruiting
4
8600
US
Naltrexone-Bupropion (NB) Combination, Placebo
Currax Pharmaceuticals
Obesity
01/29
07/29
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed
3
4223
Europe, US
ABNCoV2, Comirnaty
Bavarian Nordic
COVID-19 Disease
03/23
10/23
GMRx2_PCT, NCT04518306: Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension

Completed
3
295
Europe, US, RoW
Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, Placebo
George Medicines PTY Limited
Hypertension
09/23
10/23
GMRx2_ACT, NCT04518293: Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension

Completed
3
1385
Europe, US, RoW
Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg, Telmisartan 20 mg/amlodipine 2.5 mg ., telmisartan 40 mg/amlodipine 5 mg, Telmisartan 20 mg/indapamide 1.25 mg, telmisartan 40 mg/indapamide 2.5 mg, Amlodipine 2.5 mg/indapamide 1.25 mg, amlodipine 5 mg/indapamide 2.5 mg
George Medicines PTY Limited
Hypertension
08/23
09/23
NCT06015282: The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

Active, not recruiting
3
7741
Europe, Canada, US, RoW
Investigational aQIVc, licensed QIV1, licensed QIV2
Seqirus
Influenza, Human
03/24
01/25
NCT05258669: Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults

Recruiting
2/3
400
US
BBV152, Covaxin
Ocugen
COVID-19
09/23
10/23
NCT05288504: A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.

Completed
2
91
US
AVTX-002, CERC-002, AEVI-002, MDGN-002, Placebo
Avalo Therapeutics, Inc.
Non-Eosinophilic Asthma
05/23
05/23
Phelps, Tracey
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed
3
4223
Europe, US
ABNCoV2, Comirnaty
Bavarian Nordic
COVID-19 Disease
03/23
10/23

Download Options